Purpose: To compare corneal biomechanics between patients with ocular graft versus-host 23 disease (oGVHD) and healthy subjects (controls), and to further correlate these values with 24 ocular and hematological characteristics. 25 Materials and Methods: The following procedures were performed in oGVHD patients and 26 controls: Schirmer test (ST), break-up time (BUT), corneal and conjunctival staining, tear 27 matrix metalloproteinase-9 (MMP-9) assay (InflammaDry test, Rapid Pathogen Screening, 28 Inc, Sarasota, FL). Corneal biomechanics were calculated by using ocular response analyzer 29 (ORA, Reichert Instruments, Depew, New York, USA). The Mann-Whitney U test was used 30 to compare continuous variables between oGVHD patients and controls. Correlations of 31 corneal biomechanics with ocular and hematological parameters were examined using 32
Response Analyzer; dry eye.
Introduction
InflammaDry grading result, masked to both subject characteristics and clinical diagnosis. 115 The result was confirmed when the interpretations of at least two of the observers were in 116 agreement.
117
Ocular Surface Work-up 118 Subjective symptoms of ocular discomfort were scored by the Ocular Surface Disease Index 119 (OSDI) questionnaire. Slit-lamp examination with ocular surface staining was performed after 120 administration of 2mL of 2% fluorescein dye using the blue cobalt filter and a 7503 Boston 121 yellow filter kit to enhance staining details. Corneal and conjunctival staining were graded 122 using respectively the Oxford score [16] , and the van Bijsterveld score [17] ; Schirmer test type I and break up time (BUT) measurements were performed according to the Dry Eye test was used to compare dichotomous variables between ocular GVHD patients and control 148 subjects. Correlations of corneal biomechanical properties with demographical, hematological 149 and ocular parameters in the oGVHD group were examined using Spearman's correlation 150 analysis. A Bonferroni correction for multiple testing was used by multiplying the observed p-151 value with the number of comparisons within each analysis. A p value < 0.05 was considered 152 statistically significant.
We screened a total of 51 post-HSCT patients during the study period. Of these, 45 patients 156 fulfilled the inclusion criteria, and were finally enrolled in the study: 5 of them (11.1% of the Ocular surface parameters of oGVHD patients and control subjects are reported in Table 2 . A 172 significant difference of all parameters was found between the two groups (always p < 0.05). Patients with oGVHD showed significantly lower values of CH and CRF compared to controls (respectively, 9.4 ± 1.8 mmHg vs 11.6 ± 1.6 and 9.7 ± 1.4 mmHg vs 12.3 ± 1.3; always p < 0.001) (Table 3 ). In addition, CCT was significantly lower in oGVHD patients 181 compared to controls (510.7 ± 32.5 μm vs 537.9 ± 29.8, p < 0.001). 
189
The proportion of MMP-9 tear film positivity significantly differs between the two groups (P In patients with oGVHD, CH was significantly correlated with corneal staining (Rs = -0.316, 200 p = 0.035), conjunctival staining (Rs = -0.437, p = 0.003), Schirmer test (Rs = 0.390, p = 0.008), BUT (Rs = 0.423, p = 0.004), oGVHD severity grade (Rs = -0.383, p = 0.009), and 202 MMP-9 positivity grade (Rs=-0.429, p=0.003), while CRF was correlated only with corneal 203 staining (Rs=-0.317, p=0.034).
204
No significant correlations were found between CH and CRF values and hematological 205 characteristics (always p>0.05).
Discussion

207
The cornea is a complex biomechanical composite, and the collagen present in the Bowman's 208 layer and stroma provides the major contribution to its biomechanical behavior. [21, 22] 209 Frequently, oGVHD determines the damage of corneal epithelium that can be observed at slit However, this study did not evaluate comprehensively ocular surface parameters, and did not 225 stratify patients according to the severity of DED.
226
To the best of our knowledge, this is the first study evaluating corneal biomechanics in the 227 setting of oGVHD. This condition is a type of iatrogenic DED, whose prevalence is 228 increasing due to the widespread adoption of HSCT for the treatment of hematological 
